- Home
- SCYX vs ANTX Comparison
SCYX vs ANTX Comparison
Compare SCYX & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- ANTX
- Stock Information
- Founded
- SCYX 1999
- ANTX 2017
- Country
- SCYX United States
- ANTX United States
- Employees
- SCYX N/A
- ANTX N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- SCYX Health Care
- ANTX Health Care
- Exchange
- SCYX Nasdaq
- ANTX Nasdaq
- Market Cap
- SCYX 28.5M
- ANTX 33.2M
- IPO Year
- SCYX 2014
- ANTX 2022
- Fundamental
- Price
- SCYX $0.71
- ANTX $1.06
- Analyst Decision
- SCYX
- ANTX Buy
- Analyst Count
- SCYX 0
- ANTX 2
- Target Price
- SCYX N/A
- ANTX $2.00
- AVG Volume (30 Days)
- SCYX 115.9K
- ANTX 283.5K
- Earning Date
- SCYX 08-07-2025
- ANTX 08-12-2025
- Dividend Yield
- SCYX N/A
- ANTX N/A
- EPS Growth
- SCYX N/A
- ANTX N/A
- EPS
- SCYX N/A
- ANTX N/A
- Revenue
- SCYX $2,630,000.00
- ANTX N/A
- Revenue This Year
- SCYX $463.61
- ANTX N/A
- Revenue Next Year
- SCYX $310.80
- ANTX N/A
- P/E Ratio
- SCYX N/A
- ANTX N/A
- Revenue Growth
- SCYX N/A
- ANTX N/A
- 52 Week Low
- SCYX $0.66
- ANTX $0.87
- 52 Week High
- SCYX $2.29
- ANTX $3.07
- Technical
- Relative Strength Index (RSI)
- SCYX 39.58
- ANTX 43.41
- Support Level
- SCYX $0.70
- ANTX $1.07
- Resistance Level
- SCYX $0.75
- ANTX $1.11
- Average True Range (ATR)
- SCYX 0.05
- ANTX 0.05
- MACD
- SCYX 0.00
- ANTX 0.00
- Stochastic Oscillator
- SCYX 28.80
- ANTX 7.14
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.